|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023981,
umls-concept:C0028833,
umls-concept:C0030705,
umls-concept:C0032000,
umls-concept:C0042798,
umls-concept:C0206012,
umls-concept:C1096776,
umls-concept:C1257890,
umls-concept:C1314792,
umls-concept:C1556084,
umls-concept:C2603343
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1997-11-25
|
|
pubmed:abstractText |
The somatostatin analog octreotide has been demonstrated to improve optic tract compression caused by pituitary macroadenomas within hours of its administration and/or reduce tumor size in some patients. We report the results of a prospective multicenter study of the effects of octreotide on visual function and tumor size in patients with nonfunctioning pituitary adenomas or gonadotropin-secreting adenomas.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0148-396X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
786-95; discussion 796-7
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9316039-Adenoma,
pubmed-meshheading:9316039-Adult,
pubmed-meshheading:9316039-Aged,
pubmed-meshheading:9316039-Antineoplastic Agents, Hormonal,
pubmed-meshheading:9316039-Chemotherapy, Adjuvant,
pubmed-meshheading:9316039-Combined Modality Therapy,
pubmed-meshheading:9316039-Dose-Response Relationship, Drug,
pubmed-meshheading:9316039-Drug Administration Schedule,
pubmed-meshheading:9316039-Female,
pubmed-meshheading:9316039-Follow-Up Studies,
pubmed-meshheading:9316039-Gonadotropins, Pituitary,
pubmed-meshheading:9316039-Humans,
pubmed-meshheading:9316039-Injections, Subcutaneous,
pubmed-meshheading:9316039-Magnetic Resonance Imaging,
pubmed-meshheading:9316039-Male,
pubmed-meshheading:9316039-Middle Aged,
pubmed-meshheading:9316039-Nerve Compression Syndromes,
pubmed-meshheading:9316039-Octreotide,
pubmed-meshheading:9316039-Optic Nerve Diseases,
pubmed-meshheading:9316039-Paraneoplastic Endocrine Syndromes,
pubmed-meshheading:9316039-Pituitary Neoplasms,
pubmed-meshheading:9316039-Prospective Studies,
pubmed-meshheading:9316039-Tomography, X-Ray Computed,
pubmed-meshheading:9316039-Treatment Outcome,
pubmed-meshheading:9316039-Vision Disorders,
pubmed-meshheading:9316039-Visual Acuity,
pubmed-meshheading:9316039-Visual Fields
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group.
|
|
pubmed:affiliation |
Department of Internal Medicine, Hôpital Lariboisière, Université Paris VII, France.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
